{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-045654","form_type":"8-K","ticker":"SIGA","cik":"0001010086","company_name":"SIGA TECHNOLOGIES INC","filed_at":"2024-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.350198+00:00","generated_at":"2026-05-30T03:12:14.047310+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"SIGA reports Q3 product revenues $8.9M; receives $122M in procurement orders from US government","bullets":["Product revenues $8.9M (Q3 2024) vs $8.0M YoY; total revenues $10.0M.","Net income of $1.3M ($0.02 diluted EPS) vs net loss of $0.4M in Q3 2023.","Received $122M in procurement orders, including $112.5M from BARDA for oral TPOXX to the SNS.","Special cash dividend of $0.60/share paid April 2024, up $0.15 from prior year.","Exclusive license from Vanderbilt for preclinical monoclonal antibodies targeting orthopoxviruses."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-045654","json":"https://secwatch.observer/filing/0001140361-24-045654.json","markdown":"https://secwatch.observer/filing/0001140361-24-045654.md","text":"https://secwatch.observer/filing/0001140361-24-045654.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124045654/0001140361-24-045654-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1010086/000114036124045654/ef20038209_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T03:12:14.047310+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}